Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,870,444
  • Shares Outstanding, K 21,100
  • Annual Sales, $ 108,970 K
  • Annual Income, $ -1,640 K
  • 36-Month Beta 0.91
  • Price/Sales 26.61
  • Price/Cash Flow 142.19
  • Price/Book 7.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
126.50 +7.42%
on 12/01/17
144.82 -6.17%
on 11/16/17
-8.47 (-5.87%)
since 11/15/17
3-Month
126.50 +7.42%
on 12/01/17
149.31 -8.99%
on 11/09/17
+1.18 (+0.88%)
since 09/15/17
52-Week
95.08 +42.91%
on 02/24/17
149.31 -8.99%
on 11/09/17
+27.79 (+25.71%)
since 12/15/16

Most Recent Stories

More News
Medicines Company to Sell Infectious Disease Unit to Melinta

The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.

MLNT : 16.10 (+5.92%)
LGND : 135.88 (-0.12%)
MDCO : 27.30 (+0.18%)
ACAD : 28.98 (+0.03%)
Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?

GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

SGMO : 16.35 (-0.30%)
LGND : 135.88 (-0.12%)
CATB : 1.65 (-4.07%)
GWPH : 130.26 (-0.43%)
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

LGND : 135.88 (-0.12%)
RHHBY : 30.9000 (+0.88%)
ALKS : 52.62 (+2.06%)
BIIB : 327.94 (+1.36%)
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%

Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.

LGND : 135.88 (-0.12%)
ACHN : 2.76 (-4.50%)
JNJ : 142.46 (+0.57%)
MRK : 56.24 (+0.41%)
Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA

Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.

CORT : 16.61 (-3.82%)
LGND : 135.88 (-0.12%)
SCMP : 17.00 (+1.49%)
GSK : 34.99 (-0.71%)
AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

CORT : 16.61 (-3.82%)
LGND : 135.88 (-0.12%)
AZN : 33.13 (-0.48%)
SCMP : 17.00 (+1.49%)
Biogen Acquires Worldwide License for Alkermes' MS Candidate

Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.

LGND : 135.88 (-0.12%)
RHHBY : 30.9000 (+0.88%)
ALKS : 52.62 (+2.06%)
BIIB : 327.94 (+1.36%)
AstraZeneca Files for Label Expansion of Tagrisso in Japan

AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

LGND : 135.88 (-0.12%)
AZN : 33.13 (-0.48%)
ACHN : 2.76 (-4.50%)
RHHBY : 30.9000 (+0.88%)
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

LGND : 135.88 (-0.12%)
SCMP : 17.00 (+1.49%)
BMRN : 93.02 (+5.07%)
CPRX : 4.08 (-0.49%)
Spectrum Doubles in 3 Months: What's Driving the Rally?

Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.

SPPI : 19.04 (+2.04%)
LGND : 135.88 (-0.12%)
ANIP : 66.27 (+0.03%)
ACAD : 28.98 (+0.03%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 139.97
1st Resistance Point 138.00
Last Price 135.88
1st Support Level 135.04
2nd Support Level 134.04

See More

52-Week High 149.31
Last Price 135.88
Fibonacci 61.8% 128.59
Fibonacci 50% 122.19
Fibonacci 38.2% 115.80
52-Week Low 95.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.